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Improving clinical diagnosis of early-stage cutaneous
melanoma based on Raman spectroscopy
Inês P. Santos1, Remco van Doorn2, Peter J. Caspers1, Tom C. Bakker Schut1, Elisa M. Barroso3, Tamar E. C. Nijsten1,
Vincent Noordhoek Hegt4, Senada Koljenović4 and Gerwin J. Puppels1
BACKGROUND: Clinical diagnosis of early melanoma (Breslow thickness less than 0.8 mm) is crucial to disease-free survival.
However, it is subjective and can be exceedingly difﬁcult, leading to missed melanomas, or unnecessary excision of benign
pigmented skin lesions. An objective technique is needed to improve the diagnosis of early melanoma.
METHODS: We have developed a method to improve diagnosis of (thin) melanoma, based on Raman spectroscopy. In an ex vivo
study in a tertiary referral (pigmented lesions) centre, high-wavenumber Raman spectra were collected from 174 freshly excised
melanocytic lesions suspicious for melanoma. Measurements were performed on multiple locations within the lesions. A diagnostic
model was developed and validated on an independent data set of 96 lesions.
RESULTS: Approximately 60% of the melanomas included in this study were melanomas in situ. The invasive melanomas had an
average Breslow thickness of 0.89 mm. The diagnostic model correctly classiﬁed all melanomas (including in situ) with a speciﬁcity
of 43.8%, and showed a potential improvement of the number needed to treat from 6.0 to 2.7, at a sensitivity of 100%.
CONCLUSION: This work signiﬁes an important step towards accurate and objective clinical diagnosis of melanoma and in
particular melanoma with Breslow thickness <0.8 mm.
British Journal of Cancer (2018) 119:1339–1346; https://doi.org/10.1038/s41416-018-0257-9
INTRODUCTION
Cutaneous melanoma is a malignant tumour arising from
melanocytes, the pigment-producing cells. It is one of the most
aggressive and fatal forms of skin malignancy. Its incidence has
been steadily increasing in the last decades, with 351,880 new
cases in 2015.1
Diagnosis of melanoma at an early stage is desirable. One of the
most important prognostic factors of melanoma is the vertical
depth of growth (Breslow thickness). The Breslow thickness is
signiﬁcantly correlated with metastatic propensity. Melanoma
in situ has no associated direct mortality but carries the risk of
progressing to an invasive stage.2 Melanoma with a Breslow
thickness less than 0.8 mm can be treated surgically with a high
cure rate (5-year survival rate of >97%).2 In advanced stages, the
5-year survival rate is reported to be approximately 30%.3
The clinical diagnosis of melanoma is based on analysis of
morphological criteria and is therefore, subjective and can be
difﬁcult for general practitioner as well as dermatologist. It is
performed by visual inspection of the lesion, aided by dermo-
scopy. When a lesion is clinically suspected of melanoma, a
diagnostic excision is indicated.
It has been reported that among general practitioners, the
sensitivity of diagnosing melanoma varies between 70 and 88%
and among dermatologists between 82 and 100%.4 However, the
number needed to treat (NNT, the number of benign pigmented
lesions excised to detect one melanoma), varies between 6.3 and
8.7 by dermatologists,5,6 and between 20 and 30 for general
practitioners.5–13 The NNT can be even higher in a population
of patients <30 years (NNT= 75)7–9 or in high-risk populations
(NNT= 34, e.g. multiple dysplastic nevi or familial melanoma).10
These numbers imply that melanomas can be clinically missed,
with the risk of missing the opportunity to cure the patient, while
many unnecessary excisions of benign lesions take place. An
objective and easy-to-use technique that will support and improve
the clinical diagnosis of thin melanoma is needed to complement
the still limited diagnostic toolbox in current dermatological
practice.
The reported efforts to develop techniques to improve the
clinical diagnosis of melanoma are promising. Nevertheless,
detecting early-stage melanomas is challenging. Most methods
rely on the detection of morphological differences between
benign and malignant pigmented skin lesions.11–21 Several studies
show improvement in diagnostic accuracy of morphology-based
methods combined with dermoscopy. Yet most of these
techniques are operator dependent and subject to interpreta-
tion.12,13 Using confocal microscopy in an in vivo setting, Monheit
et al. reported a sensitivity of 98.4% and a speciﬁcity of 9.9% with
an independent validation set.22 A recent pilot study conducted
www.nature.com/bjc
Received: 20 April 2018 Revised: 6 August 2018 Accepted: 17 August 2018
Published online: 9 November 2018
1Department of Dermatology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands; 2Department of Dermatology, Leiden University Medical
Center, Leiden, Netherlands; 3Department of Oral & Maxillofacial Surgery, Special Dental Care, and Orthodontics, Erasmus MC, Erasmus University Medical Center Rotterdam,
Rotterdam, Netherlands and 4Department of Pathology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
Correspondence: Gerwin J. Puppels (g.puppels@erasmusmc.nl)
These authors contributed equally: Senada Koljenović, Gerwin J. Puppels
© Cancer Research UK 2018
by Delpueyo et al. on multispectral imaging showed a sensitivity
of 87.2% and speciﬁcity of 54.5% with an independent validation
set.17 Using in vivo reﬂectance confocal microscopy in clinically
suspicious lesions, Alarcon et al. reported a sensitivity of 97.8%
and a speciﬁcity of 92.4%, with six melanoma in situ missed.12 The
presented results are promising; however, reﬂectance confocal
microscopy is dependent on the experience of the operator.23 In a
multicentre study, 1300 lesions were analyzed by electrical
impedance spectroscopy to discriminate melanoma from benign
lesions: the observed sensitivity was 99.4%, and the speciﬁcity was
35.5% when dysplastic nevi were excluded, or 23.9% when
dysplastic nevi were included.20 In another multicentre study,
2416 lesions were analyzed by electrical impedance spectroscopy
for melanoma detection. Sensitivity of 96.6% and a speciﬁcity of
34.4% were reported.24
Compared to the morphology, biochemical tissue character-
istics are more speciﬁc.25–27 Raman spectroscopy is an optical
nondestructive technique that goes beyond morphology analysis
and characterises the tissue at a molecular level. It has been amply
demonstrated that Raman spectra can be used to distinguish
cancer from healthy tissue, including pigmented skin lesions.28–33
Lui et al. developed a classiﬁcation model to distinguish benign
pigmented lesions from melanoma, using a large Raman
measurement volume.32 Only 28% of the clinically benign lesions
were histopathologically conﬁrmed.32 The authors included in vivo
Raman measurements acquired from 44 melanomas and 286
clinically benign pigmented skin lesions. The authors reported
sensitivity of 99% and speciﬁcity of 15%. This system, Aura®-
system (Verisante, Canada), for skin cancer detection was
commercialised. In a more recent study, the same authors
increased the number of lesions (only nine melanomas were
added) in the same clinical setting and performed an independent
validation.33 In this study, the sensitivity was 99% and the
speciﬁcity was 24%.
Our group has previously demonstrated the feasibility to
acquire high-quality Raman spectra of pigmented tissue
samples in the short-wave infrared (SWIR) region.34 The study
was performed in a tertiary referral centre for high-risk patients
(familial melanoma, previous melanoma). All lesions suspicious
for melanoma based on the evaluation by specialised dermatol-
ogists aided by dermoscopy were excised for histopathological
diagnosis. In that study, we measured 124 freshly excised
melanocytic lesions. In some cases (n= 42) there was an uneven
distribution of histological components throughout the lesion,
leading to the possible sampling of nonmelanocytic tissue (e.g.
dermal collagen or skin appendages); these were referred to as
histopathologically heterogeneous lesions. Because for hetero-
geneous lesions no accurate point-to-point correlation between
the locations of the individual Raman measurements and
individual histological components could be made, these
were not used for the development of a classiﬁcation
model. Therefore, the model was limited to histopathologically
homogeneous lesions, which resulted in a speciﬁcity of 45%
and a sensitivity of 100%.31 This conﬁrms that there is
spectroscopic information in the 2820−3040 cm−1 region
(assigned to CH2−CH3 stretching vibrations), which can be
used to discriminate melanomas from benign melanocytic
lesions. The results showed that the most distinctive spectral
feature can be attributed to a higher lipid−protein ratio in
melanomas.31
In this paper, we have addressed the challenge of representa-
tive Raman sampling of melanocytic lesions. We have developed a
Raman spectroscopy method to distinguish between melanoma
and not-melanoma irrespective of the histopathological hetero-
geneity of the lesions. The fundamental requirement of the
diagnostic model was to not miss any melanoma (100%
sensitivity). The diagnostic model was validated on an indepen-
dent data set.
MATERIALS AND METHODS
Specimen handling
This study was approved by the Medical Ethics Committee of the
Leiden University Medical Center (LUMC) (C13.06). After clinical
assessment performed by a dermatologist, pigmented skin lesions
clinically suspicious for melanoma were excised according to the
national melanoma guideline and standard protocol of the LUMC
Department of Dermatology. Immediately after surgery, the
specimens were prepared for Raman spectroscopy measurements.
They were rinsed with NaCl solution (0.9%), wiped with a gauze
soaked in ethanol (70%, to remove residual ink from pen marker),
gently ﬂattened between two fused silica windows and inserted
into a custom-made specimen cartridge for Raman measure-
ments, as illustrated in Fig. 1. For detailed description, see our
previous study.31 After the Raman spectroscopy measurements,
the skin specimens were emerged in a 4% formaldehyde solution
and sent to pathology department for the routine diagnostic
procedure.
Raman spectroscopy measurements
Raman measurements were performed using an SWIR multi-
channel Raman instrument, which records in the spectral range
2780−3750 cm−1. This instrument was constructed in-house and
has been described previously.34 The light source was a diode
laser with a wavelength of 976 nm (IPS, Monmouth Junction, NJ,
USA). The light was focused on the skin lesion to a spot with a
diameter of ~6 μm. Per lesion, an average of 14 (range 9–19) point
measurements were performed in the pigmented region of the
excised lesion. Each point measurement had an integration time
of 30 s.
Calibration. All Raman spectra were corrected for the
wavelength-dependent detection efﬁciency of the instrument,
using an SRM2246 intensity standard (National Institute of
Standards and Technology, Gaithersburg, MD), as explained
elsewhere.34 The absolute wavenumber axis was calibrated using
the spectral lines of a neon−argon lamp and the Raman spectrum
of cyclohexane. The Raman background that originates from the
optics was subtracted from all spectra. Data were ﬁltered by ﬁfth-
order spline ﬁlter to remove ﬁxed pattern noise.31
Reference spectra. As reference, Raman spectra were measured
from collagen type I (Sigma-Aldrich, C7774—CAS Number 9007-
34-5). For the keratin, Raman spectra were measured in vivo from
the thick stratum corneum on the sole of the foot of a healthy
volunteer.
Moreover, a set of reference spectra from tissue with low
ﬂuorescence background and high variance of Raman signal was
created from the spectra of skin lesions used in this study, as
follows. For each spectrum, the ratio between peak content and
background content was calculated using the spectral region:
2830−3020 cm−1 (CH3 stretching vibrations, which are abundantly
present in all biological tissues). A ﬁrst-order polynomial baseline
was ﬁtted through the spectral points at 2830 and 3020 cm−1.
Peak content was calculated as the integrated area above this
baseline. Background was calculated as the integrated area below
the baseline. The spectra with the highest 40% peak to
background ratio values were selected and divided into 20
clusters using hierarchical cluster analysis. Only clusters that
consisted of more than ﬁve spectra were selected, and the
spectral average per cluster was calculated. The resulting 17
cluster average spectra were considered as an HWVN tissue
reference spectral library.
Preprocessing of Raman spectra
All Raman spectra were pre-processed in the way described
below. The software used for all computations in this study was
Matlab R2015b (Mathworks Inc., Natick, MA).
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Tissue background subtraction. A method described by Barroso
et al. based on multiple regression ﬁtting (MRF), was used for
background correction.35 MRF is an unsupervised method that
corrects ﬂuorescence spectra independently of the shape and
intensity of the Raman signal. Brieﬂy, a set of background-free library
spectra and a second-order polynomial were ﬁtted to the data using
a non-negative least squares method. As the library spectra describe
all Raman variance present in the data with minimal background
signal, the ﬁtted polynomial is a good approximation of the
ﬂuorescence background present in the data. The approximated
backgrounds were subtracted from the respective spectra.
Correction for variations in the water signal. A similar procedure
was performed to remove the inﬂuence of water signal in the CH
band. A reference spectrum of water was ﬁtted to the data. The
coefﬁcient that better approximated the water reference spectrum
for each one of the spectra measured was obtained. The water
signal multiplied by the corresponding coefﬁcient was subtracted
from the correspondent data spectra.
Scaling. All the spectra were scaled to the average of all
individual spectra using an extended multiplicative signal correc-
tion with a zero-order polynomial background36 and cropped to
the spectral range (2800−3050 cm−1), which corresponds to the
CH-stretching band region.
Detection of spectrally heterogeneous lesions. The spectral var-
iance within each lesion was calculated (in the complete range
2800−3050 cm−1). The spectral variance per lesion was then
added in the spectral direction, to have a total variance. The
variance of each lesion was normalised with respect to the
maximum variance. The lesions with a high variance (in the top
10% of the ranked values) were considered spectrally hetero-
geneous and were added to the heterogeneous lesions group.
Signal orthogonalization for keratin and collagen. A Raman
spectrum obtained from a melanocytic lesion can include
contributions from several nonmelanocytic tissue components as
mentioned above (e.g. collagen from dermis and keratin from
stratum corneum). These contributions are not informative for the
discrimination of melanocytic lesions. A method described by
Maquelin et al.37 was used to estimate the Raman signal variance
in the spectra from keratin or from collagen. The method is based
on a mathematical projection of Raman lesion spectrum on
reference spectra of keratin or collagen. The results yield the
Raman signal that cannot be distinguished from the signal of
keratin or collagen. Subsequent subtraction of this projection from
the spectrum results in the desired nonkeratin or noncollagen-
related Raman lesion spectra (i.e. the vector component of the
spectrum that is orthogonal to keratin or collagen).
In a ﬁrst step, all Raman spectra obtained from lesions were
orthogonalised with the reference spectrum of keratin. After
projection and subsequent subtraction, the integrated absolute
intensity of the orthogonalised spectrum was calculated. These
intensities were normalised to the mean value. Given the fact that
the spectra that have a low integrated absolute intensity cannot
be distinguished from the spectra of keratin, it was assumed that
the measurement was performed in a region with a thick
overlying stratum corneum. Spectra of which the integrated
intensity was below the threshold deﬁned at 0.68 (i.e. high
presence of keratin) were discarded. These Raman spectra were
dominated by keratin and considered not suitable for classiﬁca-
tion. Orthogonalised spectra on keratin that presented an
integrated area lower than 0.68 (i.e. high presence of keratin)
were labeled as “Not predicted”.
In a second step, the Raman spectra were orthogonalised with
the reference spectrum of collagen and integrated. The integrated
absolute intensities were normalised to the mean value. Lesion
spectra with an integrated intensity lower than 0.56, which means
2800 3000 3200 3400
Raman shift (cm–1)
3600
a b
d
c
Fig. 1 Schematic representation of specimen handling. a Clinical diagnosis was aided by dermoscopy (inset). b Lesions suspicious for
melanoma were excised. c Specimen is inserted in the cartridge and multiple points were measured within the lesion (inset). d Routine
histopathological evaluation (image from H&E slide)
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that the original spectra had high contribution of collagen, were
considered to be originated from nonmelanocytic structures.
These spectra were removed from the data set for model creation.
When applying the model, orthogonalised spectra with integrated
intensity lower than 0.56 were classiﬁed as not-melanoma.
Outlier detection using PCA. A PCA model was used to identify
spectral outliers. The ﬁrst ﬁve principal components, representing
99.9% of the variance in the data set, were used in the model.
Outliers were detected by projecting the spectra obtained from
lesions on the model. The spectra that could not be explained by
the model (i.e. the variance of the residual was larger than 1%)
were marked as outliers.
Histopathological evaluation and exclusion criteria
After Raman measurements, histopathological sections were
prepared as part of routine procedure and were evaluated by
two expert pathologists dedicated to this study. The ﬁnal
diagnosis, upon agreement, was used as the gold standard for
correlation with the Raman measurement, which resulted in
annotation of spectra.
All pigmented skin lesions clinically suspicious and excised for
diagnostic purpose were eligible for this study. Nonmelanocytic
lesions conﬁrmed by histopathology were excluded. Furthermore,
the classes of benign melanocytic nevi of which less than ﬁve
lesions were present in our data set were also excluded.
Grouping of lesions
For the purpose of this study, the melanocytic lesions were
divided into three groups using histopathological evaluation: (1)
homogeneous, (2) heterogeneous, and (3) dysplastic nevi (Fig. 2a).
Descriptive details were provided, as the thickness of the lesion,
depth of the lesion location in the epidermis/dermis and thickness
of stratum corneum. The heterogeneous group comprised: (a)
lesions with an uneven distribution of histological components in
the most representative H&E slide (e.g. lesion consisted of
melanocytic nests surrounded by variable amount of collagen or
other nonmelanocytic structures was considered heterogeneous);
and (b) lesions whose melanocytic structures were located outside
the Raman measurement depth of 300 µm (lesions with a stratum
corneum thickness of >300 µm and lesions located at a depth of
>300 µm beneath the surface of the skin).
Diagnostic model creation
Creation of training sets for the diagnostic model. From the
homogeneous lesions, a subset was randomly selected, referred to
as Homogenous lesions set 1 (Fig. 2a, b). This set was used to create
the PCA-LDA model (see below). Also, from the heterogeneous
lesions a subset was randomly selected, referred to as Hetero-
geneous lesions set 1. This set was used to deﬁne the parameters
for the diagnostic model. All histopathologically proven dysplastic
nevi were excluded from model creation.
PCA-LDA model. A linear discriminant analysis (LDA) model was
developed to distinguish melanomas from not-melanoma. The
PCA-LDA model was created based on averaged spectra of
Homogeneous lesions set 1. Principal component analysis (PCA)
was performed to reduce the dimensionality of the data prior to
LDA modeling. The scores of the spectra on the ﬁrst three
principal components were used as input parameter for the
model. The discriminating parameter used as input for the PCA-
LDA was a Boolean: “melanoma” or “not-melanoma”.
Parameters for the diagnostic model. The PCA-LDA model was
applied to each individual point measurement of Heterogeneous
lesions set 1. The model yields a probability for each individual
point for being melanoma. These probabilities were used to
establish the parameters of the diagnostic model. A lesion is
classiﬁed as melanoma: (1) if two or more individual point
measurements within a lesion have a PCA-LDA score higher than
0.35 and/or (2) at least one individual point measurement has a
PCA-LDA score greater than 0.8. Otherwise, the lesion is classiﬁed
as not-melanoma.
Diagnostic model validation on independent data
The diagnostic model was validated on an independent data set.
The independent validation set was comprised of remaining
homogeneous and heterogeneous lesions, referred as Homoge-
neous lesions set 2 and Heterogeneous lesions set 2 (Fig. 2a, b). The
outcome of the model was a Boolean, “melanoma” or “not-
melanoma”. Speciﬁcity was deﬁned as the fraction of correctly
predicted negatives (not-melanoma) from the total number of
common nevi. Sensitivity was calculated as the fraction of
correctly predicted positives (melanoma) from the total number
of melanomas.
Separate test on dysplastic nevi
Because there is no agreement whether dysplastic nevi must be
considered benign, they were not included either in the
diagnostic model or in the independent validation set. The
diagnostic model was separately tested on the dysplastic nevi.
RESULTS
In total, 222 freshly excised pigmented skin lesions that were
clinically suspected of melanoma were measured. From those, a
total of 48 were excluded: 17 for technical reasons (spectral
artifacts or equipment failure), 28 because these were nonmela-
nocytic (basal cell carcinoma, seborrheic wart, lichenoid keratosis,
dermatoﬁbroma, haemangioma, scar). Table S1 (supplementary
material) shows all the lesions included and excluded. In addition,
histopathological classes that contained less than ﬁve lesions
(Spitz nevus, n= 2 and combined melanocytic nevus, n= 1) were
also excluded.
The characteristics of the remaining 174 lesions are summarised
in Table 1. Of the 37 melanomas, 22 were in situ (59.4%) and 15
had an average Breslow thickness of 0.89 mm (range 0.2–3.0 mm).
Of the total 91 common nevi, 27 were dermal, 43 were compound,
16 were junctional and 5 were blue. The remaining 46 lesions were
dysplastic nevi.
Based on the criteria described for lesions classiﬁcation (see
Materials and Methods: Grouping of lesions), 76 lesions were
classiﬁed as homogeneous, 52 were classiﬁed as heterogeneous,
and 46 were dysplastic nevi. The two pathologists dedicated to
this study had or reached agreement on all diagnosed lesions.
Diagnostic model creation
A total of 78 lesions were used for model creation (Homogeneous
lesions set 1 and Heterogeneous lesions set 1). First, the Raman
spectra of the Homogeneous lesions set 1 (55 lesions) were used to
create the PCA-LDA model. The Raman spectra of the Hetero-
geneous lesions set 1 (23 lesions) were used to deﬁne the
parameters for the diagnostic model. The histopathological
diagnosis of the lesions included in the diagnostic model set are
shown in Table 2.
Figure S1 (supplementary material) shows the PCA-LDA model
discriminant for melanomas vs. common nevi and Figure S2
(supplementary material) shows the loadings of the PCA-LDA model.
Diagnostic model validation on independent data
Homogeneous lesions set 2 (21 lesions) and Heterogeneous lesions
set 2 (29 lesions) were used for the independent validation of the
diagnostic model. Table 2 shows the histopathological diagnosis
of the lesions included in the independent validation set,
comprising 17 melanomas (ten in situ and seven melanomas
with an average Breslow thickness of 0.42 mm, range 0.2–0.8 mm).
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Figure S3 (supplementary material) shows the scatter plot of the
posterior probability of lesions to belong to melanoma class, using
the PCA-LDA model and independent validation. Table 3 shows
the contingency table of the diagnostic model validation. A
speciﬁcity of 43.8 at 100% sensitivity was obtained, speciﬁcity
deﬁned as the fraction of correctly predicted negatives (not-
melanoma) from the total number of common nevi in the
independent validation set.
Eighteen common nevi were classiﬁed as melanoma, of which
seven were compound nevi, ﬁve junctional nevi, four dermal nevi
and two blue nevi. None of the melanomas was misclassiﬁed.
Two lesions were identiﬁed and labeled “Not predicted” based
on the keratin ﬁlter. Both lesions were conﬁrmed to have thick
stratum corneum by histopathology (one melanoma in situ and
one compound nevus, shown in Fig. 3).
Separate test on dysplastic nevi
The diagnostic model was separately tested on the dysplastic nevi.
From the total 46 dysplastic nevi, 73.9% were classiﬁed as
melanoma (n= 34) and 26.1% were classiﬁed as benign (n= 12).
DISCUSSION
Melanomas with a Breslow thickness of less than 0.8 mm are
curable by surgical excision. In this study, a diagnostic model for
melanoma based on Raman spectroscopy was developed and
validated on an independent test set. This is the ﬁrst Raman study
addressing thin melanomas, including melanoma in situ. The
independent validation set comprised 17 melanomas, of which 10
were in situ. Because detecting melanomas (including the early-
stage melanomas and melanomas in situ) is an important clinical
Lesions measured (n = 222)
HP evaluation (n = 205)
a
b
Melanocytic lesions included (n = 174)
Dysplastic nevi (n = 46)
Dysplastic nevi (n = 46)
+
Lesion classificationLesion classificationDiagnostic model
PCA-LDA model
HeterogeneousHomogeneous
Homogeneous
lesions set 1
(n = 55)
Homogeneous lesions set 1 (n = 55) Homogeneous lesions set 2 (n = 21)
Heterogeneous lesions set 1 (n = 23)
Heterogeneous lesions set 2 (n = 29)
Homogeneous
lesions set 2
(n = 21)
Heterogeneous
lesions set 1
(n = 23)
Heterogeneous
lesions set 2
(n = 29)
randomised
Model creation Independent validation Separate test on
dysplastic nevi
randomised
Common nevi and (in situ) melanomas (n = 128)
Excluded: Technical failure (n = 17)
Excluded:
Non-melanocytic lesions (n = 28)
Histopathological classes < 5 lesions (n = 3)
Fig. 2 a Division of lesions using the histopathological evaluation. The division was used to create the training sets for the diagnostic model
(see section “Diagnostic model creation” and b). b Lesions used for diagnostic model creation (left), lesions used for the independent
validation (middle) and dysplastic nevi on which diagnostic model was separately applied (right)
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goal for disease-free survival, the diagnostic model was optimised
for highest possible speciﬁcity at a sensitivity of 100%.
To handle the problem of the representative sampling of
melanocytes within the heterogeneous lesions, we created a PCA-
LDA model using only homogeneous lesions. This ensured that
the PCA-LDA model was based on an optimal match between
Raman measurements and the reference histopathological diag-
nosis. The PCA-LDA model discriminant visualises discriminative
spectral information between melanomas and common nevi. A
higher lipid content in melanoma is the strongest discriminative
factor (Figure S1, Supplementary material). The diagnostic model
in this study was developed to distinguish melanomas from
common nevi suspicious for melanoma.
Dysplastic nevi are melanocytic lesions that present histologi-
cally architectural disorder and cytological atypia.38,39 Because
there is no international consensus about whether dysplastic nevi
must be considered benign,39–45 dysplastic nevi were not included
in the diagnostic model. However, in clinical practice a signiﬁcant
portion of the lesions suspicious for melanoma is dysplastic nevi.
Although the dysplastic nevi were not included in the develop-
ment of the diagnostic model, we have applied the diagnostic
model on these lesions as well.
As explained in the Materials and methods section, 9−19
individual point measurements were obtained per lesion. A lesion
was classiﬁed as melanoma if two or more individual point
measurements had a PCA-LDA score higher than 0.35, or if at least
one individual point measurement had a PCA-LDA score greater
than 0.8. These criteria reﬂect a melanoma diagnosis based
Table 2. Histopathological diagnosis of lesions included in the
diagnostic model set and in the independent validation set
Histopathological
diagnosis
Number of lesions per set
Diagnostic
model set
Independent
validation set
Total
(in situ) Melanoma 20 17 37
Common
nevus
Dermal 20 7 27
Compound 27 16 43
Junctional 9 7 16
Blue 2 3 5
Total 78 50 128
Table 1. Summary of the lesions included
Histopathological diagnosis Average age Sex Anatomical Number of lesions Average Breslow thickness
(y, range) Location (mm, range)
Melanoma
In situ 58.5 (41–82) 10 female Head and neck 2
12 male Upper limb 5
Trunk 7
Lower limb 8
Invasive 52.9 (29–73) 10 female Head and neck 2 0.89
5 male Upper limb 1 (0.20–3.00)
Trunk 4
Lower limb 8
Common nevus
Dermal 43.0 (16–68) 14 female Head and neck 1
13 male Upper limb 2
Trunk 14
Lower limb 11
Compound 46.6 (15−75) 25 female Head and neck —
18 male Upper limb 4
Trunk 26
Lower limb 12
Unspeciﬁed 1
Junctional 51.5 (25−82) 10 female Head and neck 1
6 male Upper limb 2
Trunk 11
Lower limb 2
Blue 45.8 (19−87) 3 female Head and Neck 1
2 male Upper limb —
Trunk 4
Lower limb —
Dysplastic nevus 47.9 (23−77) 29 female Head and neck 1
17 male Upper limb 4
Trunk 34
Lower limb 6
Unspeciﬁed 1
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on either a single point measurement with high probability of
melanoma or multiple point measurements with moderate
probability.
A limitation of this study is the lack of accurate correlation
between the individual Raman point measurements and histo-
pathology. We are currently developing a method for reliable and
reproducible matching between the origin of individual Raman
spectra and histological structures. It is expected that, when
applying this method, the accuracy of the diagnostic model that
we have developed will be further improved.
In the independent validation, two lesions resulted in the label
“Not predicted”. For these lesions, the keratin ﬁlter had identiﬁed
the Raman measurements as nonrepresentative. We consider that
labeling nonrepresentative measurements as “Not predicted” is
important, as this avoids unnoticed misclassiﬁcations.
In this study, the NNT by dermatologists was 6.0 (222 excised
lesions suspicious for melanoma, and 37 histopathologically
conﬁrmed melanomas). Twenty percent of the excised lesions
suspicious for melanoma were dysplastic nevi. To calculate the
NNT based on Raman diagnosis, 13 randomly selected dysplastic
nevi were added to the validation set, so that this set also
comprised 20% of dysplastic nevi. If the Raman instrument were
used as an add-on to diagnose the dermatologist-selected lesions,
the estimated NNT would be 2.7 (43 lesions tested positive by
Raman spectroscopy and a total 16 histopathologically conﬁrmed
melanoma). This would represent detecting all thin melanomas
and reducing the number of unnecessary excisions by more than
twofold, when comparing with the current clinical practice. There
are indications that dysplastic nevi are associated with an
increased risk of developing melanoma,40,46–48 which is sugges-
tively supported by our results shown in the subsection “Separate
test on dysplastic nevi”.
The study was conducted on a tertiary referral center by highly
specialised dermatologists. The potential reduction of NNT to 2.7
can be even more signiﬁcant when considering the NNT reported
for nonspecialists (NNT= 20–30).5−13 To optimise the diagnostic
model for different settings the current model needs to be
expanded to include more types of suspicious skin lesions,
considering the multitude of skin lesions that dermatologists and
general practitioners have suspicions on in a more generalised
clinical practice.
We have demonstrated that an accurate diagnosis of thin
melanoma, including melanoma in situ, can be made based on
Raman spectroscopy. This signiﬁes an important step towards
accurate and objective clinical diagnosis of melanoma.
ACKNOWLEDGEMENTS
Innovatiegerichte Onderzoeksprogramma (IOP) Photonic Devices managed by
AgentschapNL, Ministry of the Economic Affairs from The Netherlands (Project
number IPD12004).
AUTHOR CONTRIBUTIONS
Conception and design (I.P.S., P.J.C., T.C.B.S., S.K., G.J.P.), Development of methodol-
ogy (I.P.S., P.J.C., T.C.B.S., E.M.B., S.K. and G.J.P.), Acquisition of data (I.P.S., R.v.D., S.K.
and V.N.H.), Analysis and interpretation of data (I.P.S., T.C.B.S., P.J.C., G.J.P. and S.K.);
Writing, review and revision of the manuscript (I.P.S., P.J.C., T.C.B.S., R.v.D., V.N.H., E.M.
B., T.E.C.N., S.K. and G.J.P.); Study supervision (P.J.C., T.C.B.S., T.E.C.N., S.K. and G.J.P.).
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41416-018-0257-9.
Competing interests: The authors declare no competing interests.
Ethics approval and consent to participate: This study was approved by the
Medical Ethics Committee of the Leiden University Medical Center (LUMC) (C13.06).
The study was conducted in compliance with the provisions of the Declaration of
Helsinki.
Table 3. Contingency table of the diagnostic model validation
Common nevus Melanoma Not predicted (high keratin)
Histopathological diagnosis Common nevus 14 18 1
Melanoma 0 16 1
1000 µ
m
250 µ
m
a b
Fig. 3 H&E-stained thin tissue sections. a Melanoma in situ with a thick stratum corneum (1200 µm); b combined melanocytic nevus with a
thick stratum corneum (200 µm). N.B.: the Raman spectra of these lesions showed high contribution from keratin and were labeled “Not
predicted” by the diagnostic model
Improving clinical diagnosis of early-stage cutaneous melanoma based on. . .
IP Santos et al.
1345
Consent for publication: All authors gave consent for publication.
Availability of data and material: The data generated during this study are
available from the corresponding author on reasonable request.
Note: This work is published under the standard license to publish agreement. After
12 months the work will become freely available and the license terms will switch to
a Creative Commons Attribution 4.0 International (CC BY 4.0).
REFERENCES
1. Karimkhani, C. et al. The global burden of melanoma: results from the Global
Burden of Disease Study 2015. Br. J. Dermatol. 177, 134–140 (2017).
2. Higgins, H. W. 2nd, Lee, K. C., Galan, A. & Leffell, D. J. Melanoma in situ: Part I.
Epidemiology, screening, and clinical features. J. Am. Acad. Dermatol. 73, 181–190
(2015).
3. Gershenwald, J. E. et al. Melanoma staging: evidence-based changes in the
American Joint Committee on Cancer eighth edition cancer staging manual. CA
Cancer J. Clin. 67, 472–492 (2017).
4. Chen, S. C., Bravata, D. M., Weil, E. & Olkin, I. A comparison of dermatologists’ and
primary care physicians’ accuracy in diagnosing melanoma: a systematic review.
Arch. Dermatol. 137, 1627–1634 (2001).
5. Sidhu, S., Bodger, O., Williams, N. & Roberts, D. L. The number of benign moles
excised for each malignant melanoma: the number needed to treat. Clin. Exp.
Dermatol. 37, 6–9 (2012).
6. Koﬂer, L., Egger, M. & Koﬂer, H. Suspicious melanocytic lesions: number needed to
treat to identify a melanoma. Clin. Dermatol. 2, 73–76 (2014).
7. Marks, R., Jolley, D., McCormack, C. & Dorevitch, A. P. Who removes pigmented
skin lesions? J. Am. Acad. Dermatol. 36, 721–726 (1997).
8. Hansen, C., Wilkinson, D., Hansen, M. & Argenziano, G. How good are skin cancer
clinics at melanoma detection? Number needed to treat variability across a
national clinic group in Australia. J. Am. Acad. Dermatol. 61, 599–604 (2009).
9. Argenziano, G. et al. Accuracy in melanoma detection: a 10-year multicenter
survey. J. Am. Acad. Dermatol. 67, 54–59 (2012).
10. Nathansohn, N., Orenstein, A., Trau, H., Liran, A. & Schachter, J. Pigmented lesions
clinic for early detection of melanoma: preliminary results. Isr. Med. Assoc. J. 9,
708–712 (2007).
11. March, J., Hand, M. & Grossman, D. Pratical application of new technologies for
melanoma diagnosis: Part I. Noninvasive approaches. J. Am. Acad. Dermatol. 72,
929–941 (2015).
12. Alarcon, I. et al. Impact of in vivo reﬂectance confocal microscopy on the number
needed to trat melanoma in doubtful lesions. Br. J. Dermatol. 170, 802–808
(2014).
13. Guitera, P. et al. Dermoscopy and in vivo confocal microscopy are complementary
techniques for diagnosis of difﬁcult amelanotic and light-coloured skin lesions.
Br. J. Dermatol. 175, 1311–1319 (2016).
14. Curiel-Lewandrowski, C. et al. Use of in vivo confocal miscroscopy in malignant
melanoma: an aid in diagnosis and assessment of surgical and nonsurgical
therapeutic approaches. Arch. Dermatol. 140, 1127–1132 (2004).
15. Guitera, P. et al. In vivo confocal microscopy for diagnosis of melanoma and basal
cell carcinoma using a two-step method: analysis of 710 consecutive clinically
equivocal cases. J. Invest. Dermatol. 132, 2386–2394 (2012).
16. Winkelmann, R. R., Yoo, J., Tucker, N., White, R. & Rigel, D. S. Assessment of a
diagnostic predictive probability model provided by a multispectral digital skin
lesion analysis device for melanoma and other high-risk pigmented lesions and
its impact on biopsy decisions. J. Clin. Aesthet. Dermatol. 7, 16–18 (2014).
17. Delpueyo, X. et al. Multispectral imaging system based on light-emitting diodes
for the detection of melanomas and basal cell carcinomas: a pilot study. J.
Biomed. Opt. 22, 0650061–0650069 (2017).
18. Yu, L., Chen, H., Dou, Q., Qin, J. & Heng, P. A. Automated melanoma recognition in
dermoscopy images via very deep residual networks. IEEE Trans. Med. Imaging 36,
994–1004 (2017).
19. Rocha, L. et al. Analysis of an electrical impedance spectrocopy system in short-
term digital dermoscopy imaging of melanocytic lesions. Br. J. Dermatol. 177,
1432–1438 (2017).
20. Mohr, P. et al. Electrical impedance spectroscopy as a potencial adjunct diag-
nostic tool for cutaneous melanoma. Ski. Res. Technol. 19, 75–83 (2013).
21. Braun, R. P. et al. Electrical impedance spectroscopy in skin cancer diagnosis.
Dermatol. Clin. 35, 489–493 (2017).
22. Monheit, G. et al. The performance of Melaﬁnd: a prospective multicenter study.
Arch. Dermatol. 147, 188–194 (2011).
23. Farnetani, F. et al. Skin cancer diagnosis with reﬂectance confocal microscopy:
reproducibility of feature recognition and accuracy of diagnosis. JAMA Dermatol.
151, 1075–1080 (2015).
24. Malvehy, J. et al. Clinical performance of the Nevisense system in cutaneous
melanoma detection: an international, multicenter, prospective and blinded
clinical trial on efﬁcacy and safety. Br. J. Dermatol. 171, 1099–1107 (2014).
25. Inamdar, G. S., Madhunapantula, S. R. V. & Robertson, G. P. Targeting the MAPK
pathway in melanoma: why some approaches succeed and other fail. Biochem.
Pharmacol. 80, 624–637 (2010).
26. Sengupta, D. & Tackett, A. J. Proteomic ﬁndings in melanoma. J. Proteom. Bioin-
form. 9, e29 (2016).
27. Carlson, J. A. et al. Molecular diagnostics in melanoma. J. Am. Acad. Dermatol. 52,
743–775 (2005).
28. Barroso, E. M. et al. Water concentration analysis by Raman spectroscopy to
determine the location of the tumour border in oral cancer surgery. Cancer Res.
76, 5945–5953 (2016).
29. Koljenovic, S. et al. Tissue characterization using high wavenumber Raman
spectroscopy. J. Biomed. Opt. 3, 0311161–03111611 (2005).
30. Nijssen, A. et al. Discriminating basal cell carcinoma from perilesional skin using
high wave-number Raman spectroscopy. J. Biomed. Opt. 12, 0340041–0340047
(2007).
31. Santos, I. P. et al. Raman spectroscopic characterization of melanoma and benign
melanocytic lesions suspected of melanoma using high-wavenumber Raman
spectroscopy. Anal. Chem. 88, 7683–7688 (2016).
32. Lim, L. et al. Clinical study of noninvasive in vivo melanoma and nonmelanoma
skin cancers using multimodal spectral diagnosis. J. Biomed. Opt. 19,
1170031–11700312 (2014).
33. Zhao, J., Lui, H., Kalia, S. & Zeng, H. Real-time Raman spectroscopy for automatic
in vivo skin cancer detection: an independent validation. Anal. Bioanal. Chem.
407, 8373–8379 (2015).
34. Santos, I. P. et al. Implementation of a novel low-noise InGaAs detector enabling
rapid near-infrared multichannel Raman spectroscopy of pigmented biological
samples. J. Raman Spectrosc. 46, 652–660 (2015).
35. Barroso E. M., et al. Characterization and subtraction of luminescence background
signals in high-wavenumber Raman spectra of human tissue. J. Raman Spectrosc.
https://doi.org/10.1002/jrs.5338 (2018).
36. Martens, H. & Stark, E. Extended multiplicative signal correction and spectral
interference subtraction: new preprocessing methods for near infrared spectro-
scopy. J. Pharm. Biomed. Anal. 9, 625–635 (1991).
37. Maquelin, K. et al. Raman spectroscopic method for identiﬁcation of clinically
relevant microorganisms growing on solid culture medium. Anal. Chem. 72,
12–19 (2000).
38. Goldstein, A. M. & Tucker, M. A. Dysplastic nevi and melanoma. Cancer Epidemiol.
Biomark. Prev. 22, 528–532 (2013).
39. Duffy, K. & Grossman, D. The dysplastic nevus: from historical perspective to
management in the modern era: part II. Molecular aspects and clinical man-
agement. J. Am. Acad. Dermatol. 67, e1–e12 (2012).
40. Shain, A. H. & Bastian, B. C. From melanocytes to melanomas. Nat. Rev. Cancer 16,
345–358 (2016).
41. Wall, N., De’Ambrosis, B. & Muir, J. The management of dysplastic naevi: a survey
of Australian dermatologists. Australas. J. Dermatol. 58, 304–307 (2017).
42. Sapra, P., Rosen, C., Siddha, S. & Lynde, C. W. Dysplastic nevus: management by
Canadian dermatologists. J. Cutan. Med. Surg. 19, 457–463 (2015).
43. Kim, C. C. et al. Addressing the knowledge gap in clinical recommendations for
management and complete excision of clinically atypical/dysplastic nevi: pig-
mented lesion subcommittee consensus statement. JAMA Dermatol. 151,
212–218 (2015).
44. Lee, K. C. et al. Variation among pathologists’ treatment suggestions for mela-
nocytic lesions: a survey of pathologists. J. Am. Acad. Dermatol. 76, 121–128
(2017).
45. Elmore, J. G. et al. Pathologists’ diagnosis of invasive melanoma and melanocytic
proliferations: observer accuracy and reproducibility study. BMJ 357, j2813
(2017).
46. Newton Bishop, J. A. Lentigos, melanocytic naevi and melanoma. In Rook’s
Textbook of Dermatology 8th edn (eds Burns, T. et al.) 54.1−54.57 (Wiley-Black-
well, USA, 2010).
47. Santa Cruz, D. J. Tumours of the skin. In Diagnostic Histopathology of Tumors 3rd
edn (ed. Fletcher, C. D. M.) 1423–1526 (Churchill Livingstone–Elsevier, UK, 2007).
48. de Vries, E. et al. Malignant melanoma: introduction. In World Health Organization
Classiﬁcation of Tumors. Pathology and Genetics of Skin Tumors (eds LeBoit, P. E.
et al.) 52–61 (IARC Press, USA, 2006).
Improving clinical diagnosis of early-stage cutaneous melanoma based on. . .
IP Santos et al.
1346
